Key facts
- This page summarizes W. Anthony Vernon's Form 4 filing for NovoCure Ltd (NVCR).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 06 Jun 2024, 17:43.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Sale
Award
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
This transaction was executed in multiple trades at prices ranging from $23.78 USD to $24.00 USD; the price reported above reflects the weighted average sale price.
Footnote F2
These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.
Footnote F3
Options to buy 6,229 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.